Tu1729 EFFICACY OF RISANKIZUMAB BY BASELINE CLINICAL, BIOCHEMICAL, AND ENDOSCOPIC DISEASE SEVERITY IN MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
- Resource Type
- Abstract
- Source
- In
Gastroenterology May 2023 164(6) Supplement:S - Subject
- Language
- ISSN
- 0016-5085